Stockscreener 앱 받기
59.06
2.56%
-1.55
시간 외 거래:
59.06
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Oruka Therapeutics(ORKA.US) Director Sells US$6.19 Million in Common Stock - Moomoo
Oruka Therapeutics director Carl Dambkowski sells $6.19m in stock - Investing.com UK
Oruka Therapeutics director Carl Dambkowski sells $6.19m in stock By Investing.com - Investing.com Canada
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors - AOL.com
Oruka Therapeutics (ORKA) director sells 105,000 shares, exercises 62,260 options - Stock Titan
105,000 common shares proposed for sale by ORKA (NASDAQ: ORKA) - Stock Titan
Oruka Therapeutics SVP Arjun Agarwal sells $607,806 in stock By Investing.com - Investing.com Australia
Oruka Therapeutics (ORKA) finance SVP sells 10,290 shares under plan - Stock Titan
Oruka Therapeutics Price Target Maintained With a $120.00/Share by HC Wainwright & Co. - Moomoo
ORKA (NASDAQ: ORKA) insiders list 22,206 common shares for sale - Stock Titan
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com Canada
ORKA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $120 - GuruFocus
How Investors May Respond To Oruka Therapeutics (ORKA) Psoriasis Data And Upsized US$700 Million Offering - Sahm
Oruka Therapeutics CMO Joana Goncalves sells $432,935 in stock - Investing.com UK
Oruka Therapeutics CMO Joana Goncalves sells $432,935 in stock By Investing.com - Investing.com Canada
Oruka Therapeutics (ORKA) CMO sells 7,000 shares after option exercises under 10b5-1 plan - Stock Titan
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Viking shows 2.67M-share stake in Oruka Therapeutics (ORKA) - Stock Titan
Oruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh Funding - Yahoo Finance
ORKA's Outperform Rating Reiterated At Wedbush, Eyes Key Psoriasis Data In 2H 2026 - RTTNews
Oruka Therapeutics (ORKA) price target increased by 50.51% to 138.41 - MSN
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $151 to $180 - Moomoo
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Oruka Reports 63.5% PASI 100 Rate for ORKA-001 at Week 16 in Psoriasis - The Clinical Trial Vanguard
ORKA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Flash (ORKA) Oruka Therapeutics Posts Q1 Per Share Loss $0.48, vs. FactSet Est of Loss $0.55 - marketscreener.com
Earnings Flash (ORKA) Oruka Therapeutics Posts Q1 Per Share Loss $0.48, Vs. FactSet Est of Loss $0.55 - Moomoo
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally - Yahoo Finance
Press Release: Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Oruka Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Oruka Therapeutics (ORKA) ramps R&D and raises over $700M in new equity - Stock Titan
ETFs Investing in Oruka Therapeutics, Inc. Stocks - TradingView
Assessing Oruka Therapeutics (ORKA) Valuation After Equity Raise Collaboration Deal And Trial Updates - Sahm
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? - The Motley Fool
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE - PR Newswire
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? - The Motley Fool
Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA) - Insider Monkey
ORKA stock is soaring after psoriasis trial results — here's why BTIG hiked its price target by 94% - MSN
Why Oruka Therapeutics (ORKA) Is Down 6.3% After $700 Million Follow-On Amid Psoriasis Breakthrough - Yahoo Finance
Oruka Therapeutics shares jump on strong psoriasis trial results - MSN
5 Best Performing Healthcare Stocks So Far in 2026 - Insider Monkey
Psoriasis Data, Halozyme Pact and Equity Raise Might Change The Case For Investing In Oruka Therapeutics (ORKA) - Sahm
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Biotech's 121.89% Potential Upside Captivates Investors - DirectorsTalk Interviews
MSN Money - MSN
Halozyme (HALO) Enters Global Partnership with Oruka Therapeutics - GuruFocus
Oruka Therapeutics (ORKA) slides 8.2% as investors digest recent $700M equity raise - Quiver Quantitative
Halozyme and Oruka sign agreement for Hypercon technology - Yahoo Finance
Halozyme Agrees to License Hypercon Technology to Oruka to Develop Psoriasis Treatment - Contract Pharma
Halozyme licenses Hypercon technology to Oruka for psoriasis drug By Investing.com - Investing.com South Africa
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
0.98%
0.12%
자본화:
|
볼륨(24시간):